Aldevron News
WEBINAR: Going Non-Viral: How Cell Therapy Manufacturing is Moving Away From Viral Vectors
March 5, 2024 / by Aldevron
Are you interested in editing cells using a CRISPR-based non-viral vector capable of achieving knock-in rates of 70–90%? Don’t miss this webinar discussing this approach and the specific strategies to improve manufacturing timelines and costs.
Past and present, viral vectors have been the gold standard for cell therapy manufacturing, but novel manufacturing modalities are now emerging in the market.
Non-viral CRISPR methods with enrichment and selection systems have improved manufacturing costs, yields, and timelines.
Learn how these specific methods generate 70–90% knock-in rates in clinically relevant cells.
Join Dr John Zuris from Editas Medicine and Dr Hyatt Blake-Want, a post-doctoral scholar at Stanford and hematology-oncology resident at Cologne University Hospital, as we discuss their novel manufacturing approaches.
WHAT TO EXPECT
Part 1: Cell therapy overview and manufacturing paradigms
- An overview of the cell therapy landscape with an emphasis on CAR-T, explaining how cost, timelines, and scale needs to be improved to fully realize the potential of these powerful therapies.
- Strategies to improve the efficiencies of non-viral-based CRISPR knock-in methods.
- Current applications of non-viral knock-in methods and important considerations of high-quality materials for translational research and clinical use.
- Future applications of an expanded therapeutic landscape: in vivo gene editing.
Part 2: A discussion of the future of cell therapies, including:
- The growing therapeutic landscape of CAR-T cells.
- The potential positive effect of innovating new manufacturing approaches for improving clinical adoption and feasibility.